Drugs in Dev. Pulmonary/Respiratory Diseases
Phase I
South Korea 
Lead Product(s) : DWN12088
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWN12088 is world's first PRS inhibitory anti-fibrotic agent,demonstrated excellent anti-fibrotic and pulmonary function improvement effects by co-administering DWN12088 and existing drugs in an animal model.
Product Name : DWN12088
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2022
Lead Product(s) : DWN12088
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DWN12088
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this study, 72 healthy adults of various ethnical backgrounds were tested for single-ascending dose test (SAD) and multiple- ascending dose test (MAD) in Australia to evaluate safety, tolerability and pharmacokinetic properties of DWN12088.
Product Name : DWN12088
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : DWN12088
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Termination
Details : Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into in July 2019 to develop BBT-877 for the treatment of idiopathic pulmonary fibrosis and various fibrotic diseas...
Product Name : BBT-877
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2020
Lead Product(s) : BBT-877
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Termination
Reset All
